Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 1.00 |
| ▸ | ESRRG | P62508 | 8/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ESRRB | O95718 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | PLD2 | O14939 | 1/20 | 1.00 |
| ▸ | PLD1 | Q13393 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afimoxifene SCHEMBL9189 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL2132301 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL640496 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL2165503 | 1.00 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL11899365 | 0.99 | ESR1 (0.97) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL9121934 | 0.97 | ESR1 (0.95) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL7649806 | 0.95 | ESR1 (0.91) | ESR1ESRRGESR2MAPTESRRB | |
| Afimoxifene SCHEMBL7649812 | 0.95 | ESR1 (0.91) | ESR1ESRRGESR2MAPTESRRB | |
| SCHEMBL9857240 | 0.95 | ESR1 (0.90) | ESR1ESRRGESR2MAPTESRRB | |
| Tamoxifen SCHEMBL1056785 | 0.95 | ESR1 (1.00) | ESR1ESRRGESR2MAPTESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255959-A1 | A SYSTEM FOR DRUG-INDUCIBLE EXPRESSION OF A POLYNUCLEOTIDE | Miltenyi Biotec B.V. & Co. KG (DE) | 2025-08-14 | — | — | US | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| EP-3551197-B1 | CHIMERIC TRANSCRIPTION FACTOR VARIANTS WITH AUGMENTED SENSITIVITY TO DRUG LIGAND INDUCTION OF TRANSGENE EXPRESSION IN MAMMALIAN CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230310385-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-3373967-B9 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-10-04 | — | — | EP | disclosed |
| US-20230242936-A1 | DUAL PROMOTER SYSTEMS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-08-03 | — | — | US | disclosed |
| CN-108174604-B | Bispecific CAR T cells for solid tumor targeting | 西雅图儿童医院（DBA西雅图儿童研究所） | 2023-06-23 | — | — | CN | disclosed |
| EP-3373967-B1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230130938-A1 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-04-27 | — | — | US | disclosed |
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| US-20190016776-A1 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2019-01-17 | — | — | US | disclosed |
| EP-3402509-A1 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | Seattle Children's Hospital (DBA Seattle Children's Research Institute) (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-3373967-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | Paracrine Therapeutics AB (SE) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017123548-A1 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2017-07-20 | — | — | WO | disclosed |
| US-9687458-B2 | Trans-clomiphene for use in cancer therapy | REPROS THERAPEUTICS INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170152297-A1 | DRUG REGULATED TRANSGENE EXPRESSION | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2017-06-01 | — | — | US | disclosed |
| WO-2017081171-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND AN ANTI ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2017-05-18 | — | — | WO | disclosed |
| US-20150283099-A1 | Trans-Clomiphene for Use in Cancer Therapy | REPROS THERAPEUTICS INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2914294-A1 | TRANS-CLOMIPHENE FOR USE IN CANCER THERAPY | Repros Therapeutics Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014070523-A1 | TRANS-CLOMIPHENE FOR USE IN CANCER THERAPY | REPROS THERAPEUTICS INC. (US) | 2014-05-08 | — | — | WO | disclosed |